Clinical trials: Cerebral Disorder
Epilepsy
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
The primary objective of this study is to determine the maximal tolerated dose (MTD) of E2007 given twice daily (bid) or once a day (qd) in patients with refractory partial-onset seizures (including secondarily generalized…
- Trial name
- NCT00144690
- Testing
- E2007 (perampanel)
- Where
- 5 sites in United States
- Sponsor
- Eisai Inc.
Hydrocephalus
A Study on the Safety of Hakim Programmable Shunt System
This study aimed to collect safety information from subjects implanted with a shunt system (trade name: Hakim Shunt Programmable System) produced by Codman \& Shurtleff, Inc. of the United States.
- Trial name
- NCT04285489
- Testing
- Hakim Shunt Programmable System
- Where
- 5 sites in China
- Volunteers
- 130 people
- Sponsor
- Integra LifeSciences Corporation
Pain, Migraine
Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine
The main purpose of this study is to compare the efficacy and safety of aspirin, acetaminophen and caffeine (AAC) with sumatriptan and placebo in the acute treatment of migraine.
- Trial name
- NCT01248468
- Testing
- Aspirin, acetaminophen and caffeine, Sumatriptan
- Where
- 20 sites in United States
- Volunteers
- 752 people
- Sponsor
- Novartis
Mild Traumatic Brain Injury
Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain Injury
The main objective of this interdisciplinary study is to develop an understanding of the molecular imaging features of blast-related mild traumatic brain injury (mTBI) in military personnel, while helping to establish assessment…
- Trial name
- NCT05337774
- Testing
- [18F]PI-2620
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Life Molecular Imaging SA.
Parkinson Disease
NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa
A 28-day phase 2a, double-blind, placebo-controlled (1:1), multi-center study of 20 mg NE3107, twice daily of safety, potential drug-drug interactions, and MDS-UPDRS defined activity in patients with Parkinson's disease .
- Trial name
- NCT05083260
- Testing
- NE3107
- Where
- 16 sites in United States
- Volunteers
- 46 people
- Sponsor
- BioVie Inc.
PARKINSON DISEASE (Disorder)
Open Label Single Arm Prebiotic Pilot Trial SR001
The goal of this pilot clinical study is to evaluate the effect of a prebiotic fiber blend in individuals diagnosed with Parkinson's Disease. The main objectives of this pilot study are: 1.
- Trial name
- NCT07127120
- Testing
- Prebiotic fiber blend
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sorridi Therapeutics
Hydrocephalus
Formative Usability Assessment of Wireless Thermal Anisotropy Devices
Measurements of shunt flow will be performed non-invasively. This study will generate usability data via observed tasks and comprehension questions to enable future device design improvements.
- Trial name
- NCT06040697
- Testing
- Thermal Anisotropy
- Where
- United States
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Rhaeos, Inc.
Huntington's Disease
A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi
The purpose of this study is to evaluate the safety, tolerability, PK, and efficacy of Pepinemab in subjects with late prodromal and early manifest Huntington's disease.
- Trial name
- SIGNAL-HD (NCT02481674)
- Testing
- VX15/2503
- Where
- 32 sites in United States, Canada
- Volunteers
- 301 people
- Sponsor
- Vaccinex Inc.
Parkinson's Disease
A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).
This is a study to evaluate the safety and efficacy of IPX066 in advanced Parkinson's disease.
- Trial name
- NCT00974974
- Testing
- IPX066, IR CD-LD
- Where
- 73 sites in United States, Canada and 6 more
- Volunteers
- 471 people
- Sponsor
- Impax Laboratories, LLC
Acute Ischemic Stroke
rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
Intravenous thrombolysis is the first-line therapy in patients with acute ischemic stroke within 4·5 hours of symptom onset, and recombinant tissue plasminogen activator (alteplase) is the preferred thrombolytic agent for this…
- Trial name
- PROST-2 (NCT05700591)
- Testing
- rhPro-UK, rt-PA
- Where
- 72 sites in China
- Volunteers
- 1,552 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Migraine
Cefalium® Compared to Tylenol® in the Treatment of Migraine Attacks
National clinical trials, phase III, randomized, open, parallel, study of superiority, in which three hundred thirty-six (336) participants of both sexes, aged between 18 and 65 years will be randomly allocated to one of two…
- Trial name
- NCT02582996
- Testing
- Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide., Acetaminophen
- Where
- 6 sites in Brazil
- Volunteers
- 336 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Acute Ischemic Stroke
Safety and Efficacy Evaluation of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO)
Prospective, Single-arm, Multi-centre Study to Evaluate the Efficacy and Safety of the iNstroke 4F Thromboaspiration Catheter in Patients with Acute Ischaemic Stroke due to Primary Distal Medium Vessel Occlusions.
- Trial name
- 4-NiVO (NCT07357285)
- Testing
- Thromboaspiration catheter
- Where
- 11 sites in Germany, Hungary and 1 more
- Volunteers
- 57 people
- Sponsor
- iVascular S.L.U.
Advanced Parkinson Disease
Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease
The primary objective of the study is to assess the effectiveness of LECIGON® treatment on the reduction in OFF time (h/day) from baseline at 12 months as measured by Movement Disorder Society-Unified Parkinson's Disease Rating…
- Trial name
- SWITCH-ON (NCT07313176)
- Testing
- No Intervention
- Where
- 4 sites in Germany, Spain and 1 more
- Volunteers
- 1 people
- Sponsor
- Britannia Pharmaceuticals Ltd.
Stroke, Ischemic
A Clinical Study of iEPC Intervent Subjects With Cerebral Hemorrhagic Stroke
This is a single centre、single arm、open-label，to investigate the safety and efficacy of EPC transplantation in the brain
- Trial name
- NCT03726814
- Testing
- EPC treatment group
- Volunteers
- 12 people
- Sponsor
- Allife Medical Science and Technology Co., Ltd.
Idiopathic Parkinson's Disease
Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease
This study aims to evaluate the effectiveness of Rotigotine and Levodopa combination therapy for younger and older patients with Parkinson's Disease under real life conditions.
- Trial name
- NEUPART (NCT02227355)
- Where
- 42 sites in France, Germany and 3 more
- Volunteers
- 195 people
- Sponsor
- UCB Biopharma S.P.R.L.
Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS)
Ilaris NIS in Korea
This is a study to evaluate safety and effectiveness of Ilaris in adult and pediatric patients receiving the drug in a clinical setting for any of the following indications, Hereditary Periodic Fever Syndromes…
- Conditions
- Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS), Colchicine Resistance Familial Mediterranean Fever (crFMF), TNF Receptor Associated Periodic Syndrome (TRAPS)
- Trial name
- REASSURE (NCT06838143)
- Testing
- Ilaris
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Huntington's Disease
Efficacy and Safety of Tetrabenazine in Chorea
The primary objective of this study was to establish the absolute reduction of chorea in participants with Huntington's disease(HD) treated with tetrabenazine or placebo
- Trial name
- NCT00219804
- Sponsor
- Prestwick Pharmaceuticals
Stroke, Neurologic Diseases, General
Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy
The main objective of this study is to evaluate the safety, tolerability and pharmacokinetics of Cerebril™ in Cerebral Amyloid Angiopathy (CAA) patients who have had lobar cerebral hemorrhage.
- Trial name
- NCT00056238
- Testing
- NC-758 (Anti amyloidotic [Aß] agent)
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bellus Health Inc. - a GSK company
Migraine With Aura, Migraine Without Aura
Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine
The purpose of this study is to evaluate the efficacy and safety of Laxymig® ER compared with placebo in prophylactic monotherapy treatment of migraine headache.
- Trial name
- NCT00334178
- Testing
- Laxymig ER (drug)
- Where
- 7 sites in Taiwan
- Volunteers
- 74 people
- Sponsor
- Lotus Pharmaceutical
Migraine
The Effect of Nasal Carbon Dioxide (CO2) in the Treatment of Mild Headache in People Who Experience Migraines
The purpose of this study is to evaluate the safety and effect of nasal carbon dioxide in the treatment of mild headaches in people who have migraines.
- Trial name
- NCT00690716
- Testing
- Nasal CO2
- Where
- 15 sites in United States
- Volunteers
- 292 people
- Sponsor
- Capnia, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.